Continuous Glucose Monitoring– tag –
-
Cohort Study Confirms Primary Care-Initiated Continuous Glucose Monitoring Significantly Improves HbA1c and Reduces Hospitalizations in Insulin-Treated Diabetics
JAMA Network Open USA Overview A new cohort study published in JAMA Network Open demonstrates that initiating Continuous Glucose Monitoring (CGM) in insulin-treated adults with diabetes through primary care clinicians leads to clinically... -
Future of Non-Invasive Blood Sugar Monitoring: High-Sensitivity Biosensors Detect Glucose in Sweat, Saliva, and Tears
Science Insight Global Overview This article envisions the future of non-invasive blood sugar monitoring, focusing on the development of high-sensitivity biosensors capable of detecting glucose in sweat, saliva, and tears. The concept of... -
Roche Diagnostics Expands Focus on Diabetes Care, Awaiting US Approval for Accu-Chek Smartguide CGM
Indianapolis Business Journal USA Overview Swiss pharmaceutical giant Roche is continuing its expansion project within its diagnostics division in Indianapolis, with an intensified focus on diabetes care. The company is particularly awai... -
Beyond Glucose: Advancements in Wearable and Implantable Biosensors Enable Continuous Monitoring of Metabolic, Hormonal, and Inflammatory Biomarkers
Frontiers Switzerland Overview This review states that wearable and implantable biosensors are shifting biochemical evaluation from episodic testing to continuous physiological monitoring of metabolic, hormonal, and inflammatory biomarke... -
Wearable and Implantable Biosensors Advance Beyond Glucose to Continuous Monitoring of Metabolic, Hormonal, and Inflammatory Biomarkers
Frontiers in Bioengineering and Biotechnology Switzerland Overview Wearable and implantable biosensors are undergoing a paradigm shift, moving beyond continuous glucose monitoring to encompass comprehensive real-time tracking of diverse ... -
FDA Clears Dexcom Stelo Glucose Biosensor as First Over-the-Counter CGM for Insulin-Naive Children Aged 2 and Up
U.S. Food and Drug Administration (FDA) USA Overview The U.S. FDA has granted the first over-the-counter (OTC) clearance for Dexcom's Stelo Glucose Biosensor System, expanding its use to insulin-naive children aged two and older. This la... -
Dexcom Stelo Secures First FDA OTC CGM Approval, Abbott Advances Freestyle Libre 3 Plus with 15-Day Wear & AID Compatibility
CNET USA Overview Dexcom's Stelo achieved the first FDA approval for an over-the-counter Continuous Glucose Monitor (CGM) in 2024, significantly broadening access for general consumers. Concurrently, Abbott's Freestyle Libre 3 Plus enter... -
ALR Technologies to Acquire CGM Medical Shenzhen, Boosting CGM Manufacturing Capacity to 300,000 Units Monthly by January 2027
ALR Technologies (Press Release) USA Overview ALR Technologies announced plans to acquire CGM Medical Shenzhen to enhance its development of accurate and affordable continuous glucose monitor (CGM) devices for diabetes management. This a... -
DexCom Expands Stelo Glucose Biosensor to Non-Insulin-Using Children, Launches Redesigned App in US July 2026
WealthMagik (via Earnings Stability Report) USA Overview DexCom announced FDA approval to expand the Stelo Glucose Biosensor to non-insulin-using children aged 2 and older, aligning with the company's mission to make glucose sensing more... -
Smartwatches Revolutionize Blood Sugar Management: Dexcom G7 and FreeStyle Libre Enhance Apple Watch Integration, Expanding AI-Driven Ecosystem
TechRepublic USA Overview Smartwatches hold the potential to transform glucose tracking, but current advancements rely on the integration of continuous glucose monitoring (CGM), artificial intelligence (AI), and regulated healthcare tech...
